Karl Olsen, MD
Ophthalmology · Fort Collins, CONPI 1275539629
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Alcon accounts for 61.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $4,384 and has fallen 52.7% since, to $2,074 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $67.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$10K
- Alcon Research LLC$1K
- Rxsight Inc$917
- Glaukos Corporation$748
- AbbVie$493
- Lensar, Inc.$482
- plus $2K from 21 others
Across 69 payments — averaging $1633.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$113K
What the payments were for
- Consulting fees$4,67430%
- Speaking & faculty fees$1,0767%
- Travel & lodging$8886%
- Food & beverage$8,63056%
- Education$1031%
- Gifts$560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 118 | $9,526 |
| Alcon Research LLC | 3 | $1,050 |
| Rxsight Inc | 7 | $917 |
| Glaukos Corporation | 10 | $748 |
| AbbVie(2 entities) | 24 | $493 |
| Lensar, Inc. | 3 | $482 |
| Bausch & Lomb Americas Inc. | 8 | $355 |
| Carl Zeiss Meditec USA, Inc. | 4 | $333 |
| Sun Pharmaceutical Industries Inc. | 5 | $226 |
| Novartis | 7 | $191 |
| Mallinckrodt Hospital Products Inc. | 9 | $186 |
| Ocular Therapeutix, Inc. | 2 | $162 |
| Harrow Eye, LLC | 3 | $152 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $107 |
| Bausch Health US, LLC | 1 | $102 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $74 |
| Shire North American Group Inc | 3 | $53 |
| Omeros Corporation | 3 | $46 |
| NEW World Medical,inc. | 1 | $40 |
| Tarsus Pharmaceuticals, Inc. | 2 | $35 |
| Rayner Intraocular Lenses Limited | 2 | $32 |
| The Cameron-ehlen Group, Inc. | 1 | $24 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $13 |
| Ivantis, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ VIVITY IOL$3,281
- AcrySof IQ PanOptix$1,314
- RXSIGHT CONTACT LENS$546
- RXSIGHT INJECTOR CARTRIDGE$546
- RXSIGHT INJECTOR HANDPIECE$546
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$546
- LIGHT ADJUSTABLE LENS (LAL)$433
- LENSAR LASER SYSTEM$428
- ReSTOR$377
- NGENUITY$285
- Centurion$261
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- VisuMax$187
- DEXTENZA$148
- Wavelight Refractive Suite$144
- VEVYE$135
- RESTASIS MULTIDOSE$126
- CEQUA$119
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
How this compares
$15,426 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 152 | $89,047 |
| RestasisCyclosporine | 69 | $64,190 |
| ProlensaBromfenac Sodium | 65 | $22,451 |
| Cyclosporine | 37 | $19,335 |
| XiidraLifitegrast | 11 | $18,978 |
| CequaCyclosporine | 21 | $15,354 |
| Alphagan PBrimonidine Tartrate | 56 | $14,321 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $13,824 |
| Prednisolone Acetate | 290 | $9,120 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $8,549 |
| Latanoprost | 552 | $6,814 |
| Ketorolac Tromethamine | 192 | $5,132 |
| Brimonidine Tartrate | 55 | $4,371 |
| Timolol Maleate | 310 | $3,274 |
| MoxifloxacinMoxifloxacin Hcl | 129 | $3,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $493 | $181,382313 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $74 | $22,45165 claims |
| Bausch & Lomb Americas Inc.Xiidra | $355 | $18,97811 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $226 | $15,35421 claims |
| AlconSimbrinza | $9,526 | $2,71411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Fort Collins
- Gary FosterFort Collins$75K
- Jason MayerFort Collins$42K
- Brittney StatlerFort Collins$8K
- Matthew AsanoFort Collins$4K
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.